Skip to main content

HLA DRB1 CWD Resolution

CPT

81382

Synonyms
  • CWD Resolution Typing
  • Share
  • Print
  • Updated on 04/14/2025

Test Details

Methodology

HLA results are obtained using Next Generation Sequencing (NGS). 

Sequence-based typing (SBT), sequence-specific oligonucleotide probes (SSOP), and/or sequence-specific primers (SSP) as needed to obtain the required resolution.

HLA results are obtained using Next Generation Sequencing (NGS). 

Result Turnaround Time

9 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Use

DRB1 antigens may be correlated with certain disease states or other clinical conditions. Also used for screening of transplant candidates and potential donors, transfusion of specifically compatible blood products, among others. This test is for single locus typing at CWD or higher resolution.

CWD resolution T\typing for HLA will meet the following criteria:

1. The typing must contain only one unambiguously assigned genotype, or

2. The typing may contain multiple alternative genotypes if one includes two Common and Well Documented (CWD) alleles and the others do not include any CWD allele. Alleles that encode identical protein sequences in the antigen recognition site (ARS) will not be resolved even if they are CWD.

3. Rare or unusual allele combinations may not be ruled out.

4. Allele codes will be reported to include those alleles that are not ruled out.

Common and well documented alleles are defined by Cano et al1 and Mack et al.2

Special Instructions

Indicate in clinical information which antigen(s) is of interest. If you have questions, please call 800-533-1037 (HLA customer service) for assistance in selecting the proper HLA test for the patient.

Limitations

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

Specimen Requirements

Specimen

Whole blood or buccal swabs

Volume

7 mL whole blood or four buccal swabs

Minimum Volume

3 mL whole blood or four buccal swabs

Container

Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. To obtain the buccal swab kit, please telephone 800-533-1037.

Storage Instructions

Maintain specimen at room temperature; protect from extreme heat or cold. Do not freeze.

Causes for Rejection

Hemolyzed specimen; clotted specimen; wrong specimen container

Footnotes

1. Cano P, Klitz W, Mack SJ, et al. Common and well-documented HLA alleles: Report of the ad-hoc committee of the American Society for Histocompatibility and Immunogenetics. Hum Immunol. 2007 May; 68(5):392-417. 17462507
2. Mack SJ, Cano P, Hollenbach JA, et al. Common and Well-Documented HLA Alleles: 2012 Update to the CWD Catalogue. Tissue Antigens. 2013 Apr; 81(4):194-203. 23510415

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
167147 HLA DRB1 (CWD) 167313 DRB1 57298-2
167147 HLA DRB1 (CWD) 167314 DRB1 57298-2
167147 HLA DRB1 (CWD) 167384 HLA Methodology 49549-9
Order Code167147
Order Code NameHLA DRB1 (CWD)
Order Loinc
Result Code167313
Result Code NameDRB1
UofM
Result LOINC57298-2
Order Code167147
Order Code NameHLA DRB1 (CWD)
Order Loinc
Result Code167314
Result Code NameDRB1
UofM
Result LOINC57298-2
Order Code167147
Order Code NameHLA DRB1 (CWD)
Order Loinc
Result Code167384
Result Code NameHLA Methodology
UofM
Result LOINC49549-9